We are currently seeking a creative and motivated Principal Scientist I/II to lead our efforts in developing next generation CRISPR-based therapeutics for CNS diseases. The Principal Scientist will be responsible for leading the research and early development activities for our CNS preclinical gene editing projects by identifying and optimizing drug candidates and assessing them in in vivo models of the disease towards the clinic. In addition, the successful candidate will be collaborating with Technology Validation, Screening, Assay Development and Gene Specificity, Viral Delivery, Non-Viral Delivery, Nucleic Acid Technologies, and in vivo Pharmacology teams as they lead the team to generate data on for efficacy, safety and mechanism of action of our novel therapeutic modalities. The successful candidate will further contribute by bringing in knowledge of neuroscience and biology, as well as upstream of R&D processes to initiate and advance CNS therapeutic programs.KEY RESPONSIBILITIES
- Contribute to the research efforts on designing, testing, optimizing and selecting lead candidates for CNS indications using our novel Mammoth Cas nuclease systems
- Lead from the bench junior and senior researchers to generate data to address CNS disorders from proof-of-concept to development candidates
- Collaboratively lead and/or supervise the development of in vitro and in vivo functional assays to assess the delivery, safety and efficacy of our therapeutics
- Present data to management, cross-functional project teams, and external partners
- Propose and integrate methodologies, technologies, and hypotheses to advance the projects and deliver high-quality data
- Hire and mentor additions to the team
- Design and execute preclinical in vitro experiments to support optimization and drug product development, and employ relevant rodent or non-human primate models to characterize gene editing candidates
- PhD in a life sciences discipline
- 6+ years of relevant CNS research post-PhD experience in an industry or academic setting
- Experience with small molecule, gene therapy or nucleic acid therapy modalities for CNS diseases
- Deep knowledge of genetic and pathophysiology of CNS diseases and relevant in vitro and animal models of diseases
- Experience with advanced primary in vitro cell culture, e.g., iPSCs, Neuron Progenitor Cells (NPCs), iPSC-d Motor neurons (iMN)
- Proficiency in standard molecular techniques, e.g., cloning strategies, PCR, library preparation for next generation sequencing, RNA handling, qPCR, etc.
- PhD in Neuroscience, Bioengineering, or related fields
- Familiarity with CRISPR technologies and gene therapy delivery systems (viral and non-viral)
- Experience with transfection methods of relevant cell types (Lipofection, nucleofection, AAV transduction)
- Immunostaining of in vitro cultured NPCs and iMN
- Experience with cDNA library generation, NGS library prep, characterization and optimization of CRISPR systems.Experience with high throughput screening systems in CNS related in vitro models
- A strong foundation in experimental documentation, basic statistical analysis and data presentation
- Bioassay development and optimization
- Excellent oral and written communication skills
- Company-paid health/vision/dental benefits
- Unlimited vacation and generous sick time
- Company-sponsored meals and snacks
- Wellness, caregiver and ergonomics benefits
- 401(k) with company matching
Base Salary Range: $118,750 - $215,250
The listed base salary range is for Mammoth employees in the Bay Area. Actual base salary will be determined by geographic work location, relevant professional experience, applicable skills, and internal equity. The base salary range for those working remotely outside of the San Francisco Bay Area may differ and will be determined by industry market data for the role and specific region.
Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company's ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth's deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.
It is our policy and intent to provide equal opportunity to all persons without regard to race, color, religion, political affiliation, sex/gender (including gender expression/identity, pregnancy, childbirth and related medical conditions), marital status, registered domestic partner status, sexual orientation, age, ancestry, national origin, veteran status, disability, medical condition, genetic characteristics, and/or any other basis protected by law. This policy covers all facets of employment including, but not limited to: recruitment, selection, placement, promotions, transfers, demotions, terminations, training, and compensation.
Mammoth Biosciences requires that all employees be vaccinated against COVID-19 as a condition of at-will employment, with exceptions for medical or religious reasons in compliance with local, state, and federal law.